NCT02726581 2023-03-27
CheckMate 602
Bristol-Myers Squibb
Phase 3 Completed
Clinical Trials
8 trialsNCT01335399 2022-09-30
ELOQUENT - 1
Bristol-Myers Squibb
Phase 3 Completed
NCT02272803 2022-06-22
Phase II Study of Lenalidomide/Dexamethasone With or Without Elotuzumab for Newly Diagnosed MM Patients in Japan
Bristol-Myers Squibb
Phase 2 Completed
NCT01239797 2022-06-01
ELOQUENT - 2
Bristol-Myers Squibb
Phase 3 Completed
NCT02159365 2019-07-16
Study of Safety of Elotuzumab Administered Over Approximately 60 Minutes in Combination With Lenalidomide and Dexamethasone for Newly Diagnosed or Relapsed/Refractory Multiple Myeloma Patients
Bristol-Myers Squibb
Phase 2 Completed
NCT01241292 2018-02-15
Japanese Study of BMS-901608 (Elotuzumab) in Combination With Lenalidomide and Low Dose Dexamethasone
Bristol-Myers Squibb
Phase 1 Completed
NCT01441973 2018-01-23
Biomarker Study of Elotuzumab in High Risk Smoldering Myeloma
Bristol-Myers Squibb
Phase 2 Completed
NCT01393964 2017-08-03
Study of Elotuzumab in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma and Various Levels of Renal Function
Bristol-Myers Squibb
Phase 1 Completed